# reload+after+2024-01-20 22:46:02.221656
address1§1111 Dr. Frederik-Philips Boulevard
address2§Suite 420
city§Montreal
state§QC
zip§H4M 2X6
country§Canada
phone§514 336 0444
website§https://www.milestonepharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
fullTimeEmployees§39
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joseph G. Oliveto M.B.A.', 'age': 55, 'title': 'CEO, President & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 905712, 'exercisedValue': 0, 'unexercisedValue': 1270320}, {'maxAge': 1, 'name': 'Mr. Amit  Hasija', 'age': 50, 'title': 'CFO & Executive VP of Corporate Development', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 603181, 'exercisedValue': 0, 'unexercisedValue': 25300}, {'maxAge': 1, 'name': 'Dr. David B. Bharucha FACC, M.D., Ph.D.', 'age': 61, 'title': 'Chief Medical Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 440674, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philippe  Douville M.B.A., Ph.D.', 'age': 61, 'title': 'Founder, Strategic Advisor & Member of Scientific Advisory Board', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeff  Nelson', 'age': 42, 'title': 'Chief Operating Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kim  Fox', 'title': 'Vice President of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Roshan  Girglani', 'title': 'Vice President of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.', 'age': 67, 'title': 'Chief Medical Advisor & Member of the Scientific Advisory Board', 'yearBorn': 1956, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Guy  Rousseau', 'title': 'SVP of Regulatory Affairs and Quality Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anita  Holz', 'title': 'VP & Head of Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.778
priceToSalesTrailing12Months§12.797985
currency§USD
dateShortInterest§1702598400
forwardEps§-1.62
exchange§NMS
quoteType§EQUITY
shortName§Milestone Pharmaceuticals Inc.
longName§Milestone Pharmaceuticals Inc.
firstTradeDateEpochUtc§1557408600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fef8fa0a-f2b8-346f-8ec3-172c3e402265
gmtOffSetMilliseconds§-18000000
targetHighPrice§25.0
targetLowPrice§3.0
targetMeanPrice§10.8
targetMedianPrice§9.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§9.593
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
